EBERT CHARLES D

Form 4

March 04, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or

Check this box

SECURITIES Form 5 obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * EBERT CHARLES D			2. Issuer Name and Ticker or Trading Symbol WATSON PHARMACEUTICALS INC [WPI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O WATS PHARMAC BONNIE C	CEUTICALS, I	(Middle) NC., 311	3. Date of Earliest Transaction (Month/Day/Year) 03/02/2011					Director 10% Owner Officer (give title Other (specify below) Sr. VP, Research & Development			
CORONA,					amendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed o	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) Execution I any (Month/Day		on Date, if	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock, par value \$0.0033	03/02/2011			A	7,119 (1)	A	\$ 0	32,268	D		
Common Stock, par value \$0.0033	03/03/2011			M	7,500	A	\$ 48.85	39,768	D		
Common Stock, par	03/03/2011			S	7,500	D	\$ 56.36	32,268 (3)	D		

value \$0.0033 (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun Underlying Securiti (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Share
Non-qualified Options to Purchase Common Stock	\$ 48.85	03/03/2011		M	7,500	04/04/2003	04/04/2011	Common Stock, par value \$0.0033	7,50

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

EBERT CHARLES D C/O WATSON PHARMACEUTICALS, INC. 311 BONNIE CIRCLE CORONA, CA 92880

Sr. VP, Research & Development

Signatures

/s/CHARLES D.

EBERT 03/04/2011

**Signature of Reporting
Person

Date

Reporting Owners 2

Edgar Filing: EBERT CHARLES D - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted shares of common stock, par value \$0.0033, were issued pursuant to the provisions of the Third Amendment and (1) Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. and will vest fifty percent (50%) on the second
- anniversary of the award date and fifty percent (50%) on the fourth anniversary of the award date.

 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.36
- to \$56.37, inclusive. The reporting person undertakes to provide to Watson Pharmaceuticals, Inc., any security holder of Watson Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- (3) Includes shares of restricted stock issued pursuant to the Third Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.